Unlock personalized cancer care. Book a Test Now
This is to bring to your notice that SOT Therapy from RGCC is not available in Singapore
Unlock personalized cancer care. Book a Test Now
This is to bring to your notice that SOT Therapy from RGCC is not available in Singapore
Q-REstrain is a breakthrough in personalized, autologous therapy for cancer—a sophisticated non-manipulated, personalized therapy that targets the specific genetic sequences driving a patient’s cancer, viral infections, or Lyme disease and inhibits expression of those genetic sequences. This innovative personalized, autologous therapy goes beyond traditional approaches by creating a uniquely tailored treatment designed specifically for individual needs.
This therapy available to various countries (excluding Singapore).
Q-REstrain takes advantage of oligonucleotide molecules – microRNAs isolated by the patient’s sample. The Q-REstrain molecule has a potent ability to block specific mRNA with a very high rate of specificity; therefore expression of only the desired gene is inhibited.
Certified RGCC practitioners receive training and support through RGCC college and the RGCC practitioner network.
Patient connects with a trained RGCC practitioner who evaluates their case and determines if Q-REstrain is a good fit.
Patient completes required diagnostic tests (Oncotrace for cancer)
Patient provides blood sample for personalized therapy development.
Customized Q-REstrain therapy is created in our state-of-the-art laboratory (14 working days).
Patient receives personalized therapy through an RGCC practitioner.
Q-REstrain therapy offers hope and healing for patients facing multiple challenging conditions:
Solid Tumors: Effective for most solid tumor types across various stages Hematologic Malignancies: Blood cancers including leukemias, lymphomas, and myelomas
Note: CNS (central nervous system) cancers are not suitable for Q-REstrain therapy
Q-REstrain successfully targets a comprehensive range of viral infections, such as:
Herpes Viruses: HSV1/HSV2, HHV6, Varicella Zoster (shingles), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV)
Human Papilloma Virus: HPV-16/18 and HPV-6/11
Hepatitis: Hepatitis B and C viruses
Other Viruses: Coxsackie Virus, HIV, HTLV1
Targeted treatment for Lyme disease and associated co-infections, helping patients overcome these complex, chronic conditions.
Reserve your 15-minute free one on one discussion
Q-REstrain therapy has been extensively studied with thousands of research studies confirming its safety profile. The therapy is well-tolerated by most patients, with a strong track record of successful outcomes across diverse patient populations.
Sample of Studies:
Safety of antisense oligonucleotide and siRNA-based therapeutics
https://www.sciencedirect.com/science/article/abs/pii/S1359644617300430
Antisense oligonucleotides as therapeutic agents
https://doi.org/10.1002/(SICI)1097-4652(199911)181:2%3C251::AID-JCP7%3E3.0.CO;2-D
In vivo and in vitro studies of antisense oligonucleotides – a review
https://pubs.rsc.org/en/content/articlehtml/2020/ra/d0ra04978f
Therapeutic Antisense Oligonucleotides Are Coming of Age
https://www.annualreviews.org/doi/abs/10.1146/annurev-med-041217-010829
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion
https://www.tandfonline.com/doi/full/10.1080/17425255.2021.1992382
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
https://www.nature.com/articles/nrneurol.2017.148
The powerful world of antisense oligonucleotides: From bench to bedside
https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wrna.1594
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
https://www.mdpi.com/612152
Antisense oligonucleotides in neurological disorders
https://journals.sagepub.com/doi/abs/10.1177/1756286418776932%20target=
For Cancer Patients:
For Viral or Lyme Patients:
Cancer: Maximum of 4 treatments per 12-month period, spaced a minimum of 3 months apart
Viral/Lyme: Maximum of 9 treatments per 12-month period, spaced a minimum of 21 days apart
Important:
Mandatory Follow-Up Tests
While generally well-tolerated, some patients may experience:
Absolute Contraindications:
Age Restrictions:
Special Considerations
Patients with large tumor burden require careful evaluation for Tumor Lysis Syndrome risk before treatment.
Patients should consult with their RGCC Practitioner about other potential contraindications.
Precision Personalization: Every Q-REstrain therapy is uniquely designed for your specific genetic profile—no one-size-fits-all approach to personalized therapy and cancer.
Long-Lasting Action: A single treatment works continuously for up to six months, providing sustained therapeutic benefit through advanced gene silencing.
Cutting-Edge Science: Utilizes the latest RNA interference technology backed by thousands of safety studies in cancer personalized therapy.
Q-REstrain therapy demonstrates remarkable success rates across different conditions:
Cancer Patients: 78% positive clinical outcome (complete response, partial response, or stable disease)
Virus-Infected Patients: 91% positive clinical outcome
Lyme Disease Patients: 95% positive clinical outcome
Clinical outcomes are defined as complete response, partial response, or disease stabilization. Individual results may vary, and success encompasses any positive response, from complete eradication to disease stabilization.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
RGCC Global Ltd
Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central, Hong Kong
202312501N
+852 7028 5202
IAS Accreditation Testing Laboratory
ISO 22000: 2018
Nr.: 20101200002689
ISO 22716: 2007
Nr.: 20019220006394
College of American Pathologists
Certificate of Accreditation
CAP#: 9239089
CLIA#: 99D2283882
Accreditation Certificate of Foreign Cell Processor
– Japanese Government
IAS Accreditation Medical Laboratory
ISO 45001: 2018
Nr.: 20152220006395
CLIA ID Number 99D2283882
Certificate of GMP Compliance
No. 512863-102689104
Production License for Investigational ATMPs for Human Use
Ref. No. 7282
©2025 Copy Right
